A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Our latest press release

Read more

20/06/2025

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

Download

To receive OSE Immunotherapeutics’ latest news